Infant Bacterial Therapeutics
Lars-Olof "Lollo" Eriksson has an extensive work history in the pharmaceutical and clinical research industry. Lars-Olof "Lollo" has held various leadership roles, including CEO and Chief Commercial Officer at Trialbee AB, as well as Executive Vice President at ICON plc. Their experience also includes positions at PAREXEL International and Merck, where they served as Vice President and Sr. Director, respectively. Currently, they are a Strategic Advisor at Curebase and Infant Bacterial Therapeutics AB, focusing on clinical development and growth opportunities within the industry.
Lars-Olof "Lollo" Eriksson earned their Ph.D. in Clinical Pharmacology from Uppsala and Lund University in Sweden from 1984 to 1989.
This person is not in any offices
Infant Bacterial Therapeutics
IBT is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.